MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia. The therapeutic area is currently dominated by Neulasta® and Neulasta® Onpro®, and a range of biosimilars who are also making headway in the market.
Learn how you can use P&T Perspectives to: